Published in Int J Cancer on January 01, 2007
Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression. Mol Ther (2009) 1.40
NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma. Cancer (2012) 1.13
Immunotherapy targets in pediatric cancer. Front Oncol (2012) 0.97
Cancer-testis (CT) antigen expression in medulloblastoma. Cancer Immun (2008) 0.94
MAGE-A1 expression is associated with good prognosis in neuroblastoma tumors. J Cancer Res Clin Oncol (2008) 0.91
IRF1 and NF-kB restore MHC class I-restricted tumor antigen processing and presentation to cytotoxic T cells in aggressive neuroblastoma. PLoS One (2012) 0.84
T-Cell-Based Immunotherapy for Osteosarcoma: Challenges and Opportunities. Front Immunol (2016) 0.84
Immunotherapy of Childhood Sarcomas. Front Oncol (2015) 0.81
Selective cancer-germline gene expression in pediatric brain tumors. J Neurooncol (2008) 0.78
Human rhabdomyosarcoma cells express functional erythropoietin receptor: Potential therapeutic implications. Int J Oncol (2015) 0.78
Genetically modified T-cell therapy for osteosarcoma. Adv Exp Med Biol (2014) 0.77
Immunotherapy for Bone and Soft Tissue Sarcomas. Biomed Res Int (2015) 0.76
Does it make sense to target one tumor cell chemotactic factor or its receptor when several chemotactic axes are involved in metastasis of the same cancer? Clin Transl Med (2016) 0.75
Targeted immunotherapy for pediatric solid tumors. Oncoimmunology (2015) 0.75
Patterns of somatic mutation in human cancer genomes. Nature (2007) 38.41
Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature (2004) 8.35
Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res (2005) 7.66
A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer. Nat Genet (2005) 6.70
Sequence variant on 8q24 confers susceptibility to urinary bladder cancer. Nat Genet (2008) 6.69
Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat Biotechnol (2005) 5.80
Human dectin-1 deficiency and mucocutaneous fungal infections. N Engl J Med (2009) 5.27
Human T cell responses against melanoma. Annu Rev Immunol (2006) 4.99
Toll-like receptor 2 controls expansion and function of regulatory T cells. J Clin Invest (2006) 4.72
Dendritic cell immunotherapy: mapping the way. Nat Med (2004) 4.28
Physical limits of cell migration: control by ECM space and nuclear deformation and tuning by proteolysis and traction force. J Cell Biol (2013) 3.77
The dendritic cell-specific adhesion receptor DC-SIGN internalizes antigen for presentation to T cells. J Immunol (2002) 3.48
C-type lectin receptors on dendritic cells and Langerhans cells. Nat Rev Immunol (2002) 3.44
Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat Rev Immunol (2007) 3.42
Relationship between apparent diffusion coefficients at 3.0-T MR imaging and Gleason grade in peripheral zone prostate cancer. Radiology (2011) 3.04
Membrane protein GARP is a receptor for latent TGF-beta on the surface of activated human Treg. Eur J Immunol (2009) 2.71
Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases. Cancer Res (2011) 2.63
Syk kinase is required for collaborative cytokine production induced through Dectin-1 and Toll-like receptors. Eur J Immunol (2008) 2.62
Nucleotide-binding oligomerization domain-2 modulates specific TLR pathways for the induction of cytokine release. J Immunol (2005) 2.52
Different faces of the heme-heme oxygenase system in inflammation. Pharmacol Rev (2003) 2.52
Transition zone prostate cancer: detection and localization with 3-T multiparametric MR imaging. Radiology (2012) 2.47
Online focus groups as a tool to collect data in hard-to-include populations: examples from paediatric oncology. BMC Med Res Methodol (2009) 2.38
Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL. Blood (2013) 2.34
Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res (2003) 2.32
The C-type lectin DC-SIGN (CD209) is an antigen-uptake receptor for Candida albicans on dendritic cells. Eur J Immunol (2003) 2.30
TRPM7, a novel regulator of actomyosin contractility and cell adhesion. EMBO J (2006) 2.20
An antigen produced by splicing of noncontiguous peptides in the reverse order. Science (2006) 2.18
Tumor-specific shared antigenic peptides recognized by human T cells. Immunol Rev (2002) 2.18
The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells. Immunology (2013) 2.14
Dectin-1 synergizes with TLR2 and TLR4 for cytokine production in human primary monocytes and macrophages. Cell Microbiol (2008) 2.11
Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination. Cancer Res (2012) 2.08
In situ tumor ablation creates an antigen source for the generation of antitumor immunity. Cancer Res (2004) 2.06
NOD2 and toll-like receptors are nonredundant recognition systems of Mycobacterium tuberculosis. PLoS Pathog (2005) 2.04
Functional T cells targeting NY-ESO-1 or Melan-A are predictive for survival of patients with distant melanoma metastasis. J Clin Oncol (2012) 1.97
Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice. J Clin Invest (2011) 1.91
The clinical epidemiology of urachal carcinoma: results of a large, population based study. J Urol (2012) 1.88
Myosin II and mechanotransduction: a balancing act. Trends Cell Biol (2007) 1.85
Targeted delivery of TLR ligands to human and mouse dendritic cells strongly enhances adjuvanticity. Blood (2011) 1.83
DNA methylation profiling reveals a predominant immune component in breast cancers. EMBO Mol Med (2011) 1.81
Targeting DCIR on human plasmacytoid dendritic cells results in antigen presentation and inhibits IFN-alpha production. Blood (2008) 1.79
Toll-like receptors on regulatory T cells: expanding immune regulation. Trends Immunol (2006) 1.77
How C-type lectins detect pathogens. Cell Microbiol (2005) 1.77
Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen. J Exp Med (2005) 1.75
Clinical epidemiology of nonurothelial bladder cancer: analysis of the Netherlands Cancer Registry. J Urol (2010) 1.74
Identification of different binding sites in the dendritic cell-specific receptor DC-SIGN for intercellular adhesion molecule 3 and HIV-1. J Biol Chem (2002) 1.71
Prognostic significance and mechanism of Treg infiltration in human brain tumors. J Neuroimmunol (2010) 1.70
Management of inflammatory bowel disease in pregnancy. J Crohns Colitis (2012) 1.69
In vivo assessment of prostate cancer aggressiveness using magnetic resonance spectroscopic imaging at 3 T with an endorectal coil. Eur Urol (2011) 1.68
CD4+FoxP3+ regulatory T cells gradually accumulate in gliomas during tumor growth and efficiently suppress antiglioma immune responses in vivo. Int J Cancer (2007) 1.64
Toll-like receptor expression and function in human dendritic cell subsets: implications for dendritic cell-based anti-cancer immunotherapy. Cancer Immunol Immunother (2010) 1.60
Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma. Am J Respir Crit Care Med (2010) 1.60
Hotspots of GPI-anchored proteins and integrin nanoclusters function as nucleation sites for cell adhesion. Proc Natl Acad Sci U S A (2009) 1.60
Skeletal muscle ultrasound: correlation between fibrous tissue and echo intensity. Ultrasound Med Biol (2008) 1.59
European genome-wide association study identifies SLC14A1 as a new urinary bladder cancer susceptibility gene. Hum Mol Genet (2011) 1.58
Effective induction of naive and recall T-cell responses by targeting antigen to human dendritic cells via a humanized anti-DC-SIGN antibody. Blood (2005) 1.57
Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin Cancer Res (2003) 1.57
Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma. Int J Cancer (2005) 1.55
High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens. J Exp Med (2005) 1.55
Dual function of C-type lectin-like receptors in the immune system. Curr Opin Cell Biol (2003) 1.53
A human endogenous retroviral sequence encoding an antigen recognized on melanoma by cytolytic T lymphocytes. Cancer Res (2002) 1.51
Dendritic cell interaction with Candida albicans critically depends on N-linked mannan. J Biol Chem (2008) 1.50
(19)F MRI for quantitative in vivo cell tracking. Trends Biotechnol (2010) 1.49
Immunomonitoring tumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome. J Clin Oncol (2005) 1.48
Microdomains of the C-type lectin DC-SIGN are portals for virus entry into dendritic cells. J Cell Biol (2004) 1.48
Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a phase I/II study in metastatic melanoma patients. Clin Cancer Res (2010) 1.45
Clinical and immunologic responses in melanoma patients vaccinated with MAGE-A3-genetically modified lymphocytes. Int J Cancer (2012) 1.45
Assessment of prostate cancer aggressiveness using dynamic contrast-enhanced magnetic resonance imaging at 3 T. Eur Urol (2013) 1.44
Sensitivity of magnetic resonance imaging of dendritic cells for in vivo tracking of cellular cancer vaccines. Int J Cancer (2007) 1.42
The Bt-DUX: development of a subjective measure of health-related quality of life in patients who underwent surgery for lower extremity malignant bone tumor. Pediatr Blood Cancer (2009) 1.42
Prevalence of von Hippel-Lindau gene mutations in sporadic renal cell carcinoma: results from The Netherlands cohort study. BMC Cancer (2005) 1.41
Neogenesis of lymphoid structures and antibody responses occur in human melanoma metastases. Cancer Res (2012) 1.41
Peptide fine specificity of anti-glycoprotein 100 CTL is preserved following transfer of engineered TCR alpha beta genes into primary human T lymphocytes. J Immunol (2003) 1.41
The heme-heme oxygenase system: a molecular switch in wound healing. Blood (2003) 1.39